Scientific studies have verified that cancer is caused by the genetic mutation of human body, genetic mutation can lead to infinite proliferation of cells due to losing of normal control ability, eventually resulting in occurrence of cancer. While the targeted drugs can kill the tumor cells carrying specific gene variations, with apparent curative effects, therefore in several kinds of cancers, it is regarded as the first choice of treatment for advanced cancer patients. As for different patients, the genovariation they carry also have a tremendous difference, such differences cause the different sensitivity and toxicity reaction of each patient with the same targeted drug. In the guideline of cancer in United States (NCCN) clearly recommend that patients with colorectal cancer must detect the status of genetic mutation of KRAS, NRAS and BRAF and so on before using Cetuximab.
The precision diagnosis is a prerequisite for precise medication. The idea of molecular genotype makes the doctors formulate best therapeutic regimen according to biomarkers carried by colorectal cancer patients and corresponding clinical status, to greatly find out potentially available targeted drugs and enhance treatment efficiency of antineoplastic drugs.
The occurrence of tumors is often accompanied by multiple gene variations and heterogeneity. As more and more driver genes of colorectal cancer targets have been found, the traditional single detection technology can’t meet the current detection needs. The second generation sequencing technology can realize parallel detection on multiple genes, saving samples compared to traditional detection methods and reaching higher technology sensitivity, to restore tumor mutation in a more real manner.